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Transforming growth factor-b1 regulates chemokine and complement
production by human proximal tubular epithelial cells. Previously it has
been demonstrated that human proximal tubular epithelial cells (PTEC)
are able to produce chemokines (such as IL-8 and MCP-1) and comple-
ment components (such as C2, C3, C4 and factor H), and that production
of these proteins is regulated by pro-inflammatory cytokines such as
interleukin-1a (IL-1a), tumor necrosis factor-a (TNF-a) and interferon-g
(IFN-g). Since TGF-b is also expressed in the renal interstitium during
inflammation, we investigated the effect of TGF-b on the production of
chemokines and complement components by PTEC in culture. Transform-
ing growth factor-b1 up-regulated IL-8 production by an average of 4.11 6
1.0-fold. macrophage chemoattractant phagocyte (MCP-1) production, on
the other hand, was down-regulated by TGF-b1 by an average of 2.2 6
0.7-fold. The production of C3 and C4 was also down-regulated after
incubation with TGF-b1 (1.9 6 0.3- and 3.0 6 1.2-fold, respectively). All
effects were dose- and time-dependent and were found to be specific for
TGF-b1, as assessed by inhibition of the effect with a neutralizing antibody
against TGF-b1. These data, together with the knowledge that TGF-b,
chemokines and complement components play a role in several types of
renal disease, suggest that TGF-b is involved in the regulation of local
expression of chemokines and complement components by tubular cells.
The transforming growth factor-beta (TGF)-b family is com-
posed of a group of pleiotropic cytokines that are involved in
proliferative, inductive and regulatory effects on a wide variety of
cell types [1, 2]. Transforming growth factor-b is an important
immunomodulator, influencing inflammatory events during vari-
ous phases of inflammation [3, 4]. It is known, for instance, that
TGF-B regulates the production of acute phase proteins, and it is
involved in monocyte recruitment and activation [5–7]. For mono-
cytes, TGF-b has been shown to down-regulate the expression of
CD32 (IgG Fc receptor type II) and CD89 (FcaR) [8, 9].
Furthermore, TGF-b inhibits complement C3 gene expression in
astrocytes [10]. In addition, it has been shown that TGF-b
regulates the induction of chemokines in neutrophils, bone mar-
row stromal cells, astrocytes and osteocytes [11–14]. In renal
disease it has been shown that TGF-b plays an important role in
the fibrogenesis of renal diseases [15, 16]. Expression of TGF-b
mRNA in renal tissue has been demonstrated in biopsies of
patients with IgA nephropathy [17], interstitial fibrosis [18] and in
acute and chronic renal allograft rejection [19, 20]. It is thought
that regulation of extracellular matrix production is one of the
main effects of TGF-b in the kidney [21–25]. However, since
TGF-b is involved in inflammatory processes, such as leukocyte
attraction and acute phase protein production, we hypothesized
that TGF-b might also be involved in the regulation of chemokine
and complement production by renal cells. It has been reported
that expression of these factors is found in renal tissue in different
renal diseases, such as renal transplant rejection and tubulointer-
stitial nephritis [26–36].
Previously we have demonstrated that human proximal tubular
epithelial cells are able to produce chemokines like macrophage
chemoattractant phagocyte-1 (MCP-1), interleukin-8 (IL-8) and
RANTES, and complement components C2, C3, C4, factor H and
factor B [37–41]. In the present study we found that TGF-b1
enhances IL-8 production by PTEC in culture, while it down-
regulates MCP-1 and complement synthesis.
METHODS
Proximal tubular epithelial cell cultures
Seven different primary human proximal tubular epithelial cell
(PTEC) lines were obtained from kidney tissue anatomically
unsuitable for transplantation or from healthy nephrectomy spec-
imens as described previously [38, 42]. In brief, PTEC monolayers
were cultured in serum-free DMEM/Ham’s F12 media in a 1:1
ratio (Seromed Biochem KG, Berlin, Germany) supplemented
with insulin (5 mg/ml), transferrin (5 mg/ml), selenium (5 ng/ml),
hydrocortisone (36 ng/ml), tri-iodothyronine (40 pg/ml) and epi-
dermal growth factor (10 ng/ml) (all from Sigma Chemical Co., St.
Louis, MO, USA). The primary cell lines were grown on wells
coated with a matrix of bovine collagen type I (Sigma Chemical
Co.) and decomplemented fetal calf serum (DFCS) (Life Tech-
nologies Inc., Gaithersburg, MD, USA) in serum free medium.
Explanted cultures were characterized by their morphological
appearance, immunofluorescence [42–44] and by FACS analysis
with antibodies directed to two surface peptidases, namely anti-
adenosine deaminase binding protein antibody (ADBP/CD26;
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kindly provided by Dr. Dinjens, University Hospital Maastricht,
the Netherlands), and anti-leucine amino peptidase antibody
(LAP; kindly provided by Dr. De Broe, University of Antwerp,
Belgium) [40, 45]. Proximal tubular epithelial cells used for the
experiments were cultured in 24-well tissue culture plates in
serum free medium and were from the third to seventh passages.
As judged from the expression of the two surface peptidases
CD26 and LAP, no detectable changes in the phenotype of the
cells occurred during passage of the cells.
Stimulation with transforming growth factor-b1
Proximal tubular epithelial cells grown in T25 flasks were
trypsinized with 0.05% (wt/vol) trypsin/0.02% (wt/vol) EDTA
(Sigma) and seeded in 24-well plates at a cell concentration of 1 3
105 cells per well. After 24 hours the wells were washed with
serum-free culture medium and incubated with 1 ml culture
medium supplemented with biologically active TGF-b1 or
TGF-b2 (R&D Systems, Abingdon, UK). The supernatants were
harvested and assessed for the chemokines IL-8, MCP-1 and
RANTES and complement components C2, C3, C4, factor H, all
by sandwich ELISA. The cells in all wells were trypsinized and
counted using a Coulter Counter (Coulter Electronics, Mijdrecht,
The Netherlands).
In selected experiments PTEC were incubated with TGF-b1 in
the presence or absence of a neutralizing monoclonal antibody
2G7 directed against TGF-b1 [46]. After 48 hours of incubation
the supernatants were harvested and assessed for chemokine and
complement production. All experiments were performed in
triplicate.
Chemokine sandwich ELISAs
The chemokines MCP-1, IL-8 and RANTES were quantified
using sandwich ELISAs as described previously [39, 47]. In brief,
wells of 96-well microtiter plates (Greiner, Alphen aan de Rijn,
the Netherlands) were coated with a MoAb anti-human MCP-1
(R&D Systems), MoAb anti-IL-8 (CLB, Amsterdam, the Nether-
lands) or MoAb anti-RANTES (R&D Systems) overnight at
room temperature. Nonspecific binding sites were blocked with
PBS/0.01% Tween/2% casein. After one hour of incubation at
37°C the plates were washed with PBS/0.01% Tween and samples
were added to the wells and incubated for one hour at 37°C. The
plates were washed and incubated subsequently with rabbit anti-
MCP-1, anti-IL-8 or anti-RANTES for one hour at 37°C, washed
again and reacted with goat anti-rabbit IgG-HRP (Jackson Im-
muno Research Lab. Inc., West Grove, PA, USA). Bound HRP
was developed using 2,29-Azino-bis(3-Ethylbenzthiazoline-6-sul-
fonic acid) (Sigma) as a substrate followed by measurement of the
optical density at 415 nm. A standard curve was constructed using
a standard with known concentrations of MCP-1, IL-8 or recom-
binant human RANTES (PreproTech, London, UK).
Complement sandwich ELISAs
Complement components C2, C3, C4, and factor H were
quantified by sandwich ELISA as described previously [40, 41]. In
brief, wells of 96-well microtiter plates (Greiner) were coated with
affinity-purified polyclonal anti-human C2, C3, C4 or factor H for
two hours at 37°C, no additional saturation step were required.
After washing, 100 ml samples were diluted appropriately to fall
within the standard range and incubated for one hour at 37°C.
The plates were washed and incubated subsequently with a
corresponding digoxigenin (DIG)-conjugated affinity-purified
rabbit anti-human complement C2, C3, C4, or factor H and
horseradish-peroxidase conjugated sheep F(ab)2 anti-DIG poly-
clonal antibody (Boehringer Mannheim Biochemica). The plates
were developed using 2,29-Azino-bis(3-Ethyl benzthiazoline-6-
sulfonic acid; Sigma) as a substrate and the optical density was
measured at 415 nm. A standard curve was constructed using
pooled normal human serum with known concentrations of the
various complement components.
RESULTS
Dose dependent response to transforming growth factor-b1
To determine whether the effect of TGF-b1 on chemokine and
complement production was dose-dependent, three PTEC lines
(numbers 1, 2 and 3 in Table 1) were exposed to increasing
concentrations of TGF-b1 (0.3 to 1.8 ng/ml TGF-b1) and after 72
hours the supernatants were collected and assessed for IL-8,
MCP-1, C3 and C4 production. As depicted in Figure 1A, TGF-b1
induced a dose-dependent increase of IL-8 production in all three
PTEC lines. The production of MCP-1, however, was also de-
creased in a dose dependent manner (Fig. 1B). Similar results
were obtained for C3 and C4 production (Fig. 1C, D). Sub-
optimal effects of TGF-b1 on chemokine and complement pro-
duction were obtained after incubation with 0.6 ng/ml TGF-b1.
Table 1. Production of IL-8 and MCP-1 by different PTEC lines for 72
hours, in the presence or absence of 1.8 ng/ml TGF-b1
Cell line
IL-8 ng/ml MCP-1 ng/ml
Medium TGF-b1 Medium TGF-b1
PTEC-1 3.1 6 0.5 8.1 6 0.3 4.3 6 0.2 2.2 6 0.1
PTEC-2 2.7 6 0.4 16.0 6 1.5 5.2 6 0.3 1.8 6 0.1
PTEC-3 2.0 6 0.4 7.3 6 0.7 3.1 6 0.2 0.9 6 0.1
PTEC-4 4.2 6 0.3 20.1 6 2.1 9.5 6 0.4 6.0 6 0.6
PTEC-5 1.0 6 0.2 4.9 6 0.5 2.2 6 0.3 0.9 6 0.2
PTEC-6 2.3 6 0.3 7.5 6 0.9 7.3 6 0.5 5.4 6 0.4
PTEC-7 3.7 6 0.2 15.4 6 1.3 4.5 6 0.3 2.3 6 0.4
Data are mean 6 SD (N 5 3). Abbreviations are: IL-8, interleukin-8;
MCP-1, macrophage-1; PTEC, proximal tubular epithelial cell; TGF-b1,
transforming growth factor-b1.
Table 2. Production of complement C3 and C4 by different PTEC lines
for 72 hours, in the presence or absence of 1.8 ng/ml TGF-b1
Cell line
Complement C3
ng/ml
Complement C4
pg/ml
Medium TGF-b1 Medium TGF-b1
PTEC-1 34.6 6 1.6 18.2 6 2.1 651 6 10.2 222 6 10.2
PTEC-2 15.5 6 1.5 6.1 6 1.0 1255 6 10.6 350 6 9.8
PTEC-3 21.9 6 2.3 13.1 6 1.2 905 6 10.3 188 6 5.6
PTEC-4 13.5 6 1.2 7.3 6 0.9 , 100a , 100a
PTEC-5 7.6 6 1.1 3.8 6 1.0 , 100a , 100a
PTEC-6 18.1 6 2.1 9.5 6 1.3 346 6 7.5 208 6 8.9
PTEC-7 16.9 6 1.6 8.7 6 2.0 222 6 7.3 , 100a
Data are mean 6 SD (N 5 3). Abbreviations are in Table 1.
a Lower than the detection limit of the ELISA.
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Effect of transforming growth factor-b1 on chemokine and
complement production
To further analyze the effect of TGF-b1 on human proximal
tubular epithelial cells (PTEC), subcultures of seven different
primary PTEC lines were incubated with 1.8 ng/ml TGF-b1. After
72 hours the supernatants were harvested and assessed for the
chemokines IL-8, MCP-1 and RANTES, and complement com-
ponents C2, C3, C4, and factor H. The production of IL-8 by the
different cell lines varied from 1.0 6 0.2 to 4.2 6 0.3 ng/ml IL-8
per 72 hours. The presence of 1.8 ng/ml TGF-b1 resulted in
increased production of IL-8 in all seven PTEC lines with an
average of 4.11 6 1.0-fold increase (Table 1). The baseline
production of MCP-1 ranged between 2.2 6 0.3 and 9.5 6 0.4
ng/ml MCP-1 per 72 hours. Incubation with TGF-b1 resulted in a
decreased production with an average of 2.2 6 0.7-fold. No effect
of TGF-b1 was observed on RANTES production. In the case of
complement production, the baseline production was variable
between the seven lines, and again down-regulation of the pro-
duction of complement C3 and C4 was observed after incubation
with TGF-b1. In all PTEC lines the C3 production was decreased
after incubation with TGF-b1 by an average of 1.9 6 0.3-fold
(Table 2). Production of C4 was observed in five out of seven
PTEC lines. Incubation with TGF-b1 resulted in decrease of the
production C4 by an average of 3.0 6 1.2-fold. No detectable C2
production was found in either of the seven PTEC lines. Factor H
production was found in six out of seven lines, however, no up- or
down-regulation of production was seen with TGF-b1 (data not
shown).
Kinetics of the transforming growth factor-b1 induced effects
The regulation of TGF-b1 was found to be time-dependent.
After incubation with 0.6 ng/ml TGF-b1 for 24, 48 and 72 hours,
a time-dependent increase of IL-8 production and a time depen-
dent decrease of MCP-1 production was observed (Fig. 2 A, B).
Fig. 1. Effect of increasing concentrations of transforming growth factor-B1 (TGF-b1) on chemokine and complement production by proximal tubule
epithelial cells (PTEC). The PTEC lines 1 (M), 2 () and 3 (E) were cultured in the presence of increasing concentrations of TGF-b1, and after 72
hours the supernatants were harvested and assessed for interleukin-8 (IL-8; A), macrophage chemattractant phagocyte-1 (MCP-1; B), and complements
C3 (C) and C4 (D) production by sandwich ELISA. The production in the absence of TGF-b1 for each of the cell lines was adjusted at 1.0. Increases
or decreases relative to the baseline production are indicated on the ordinate, while TGF-b concentrations are depicted on the abscissa. Each point
represents the mean 6 SD (N 5 3).
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Already at 24 hours a 2.4-fold increase in the IL-8 production
could be observed, whereas the maximal decrease in MCP-1
production was observed at 48 hours. The results of the kinetic
experiments for complement components C3 and C4 are depicted
in Figure 3, C and D. For both C3 and C4 a maximal decrease in
the production was observed at 72 hours with an 1.7- and 1.8-fold
decrease, respectively.
Inhibition of the effect of transforming growth factor-b1 by a
monoclonal antibody against TGF-b1
To determine the specificity of the observed effects of TGF-b1
on chemokine and complement production, PTEC lines 1 and 2
were incubated with 0.6 ng/ml TGF-b1 in the presence or absence
of a neutralizing anti-TGF-b1 monoclonal antibody 2G7 [41].
After 48 hours the supernatants were harvested and assessed for
IL-8, MCP-1, C3 and C4 production. The effect of TGF-b1 on
IL-8, MCP-1, C3 and C4 production was completely abrogated by
the neutralizing anti-TGF-b antibody, as depicted for IL-8 and
MCP-1 in Figure 3. A control antibody had no detectable effect
on the TGF-b1 induced effects. Results similar to that for MCP-1
were obtained for C3 and C4, namely, that the neutralizing
antibody abrogated the TGF-b1 down-regulation. No effect was
observed with a control antibody.
DISCUSSION
Progressive renal disease such as glomerulonephritis and dia-
betic nephropathy are characterized by glomerulosclerosis and
tubular atrophy. Several studies have suggested that TGF-b has
an important role in the pathogenesis of these diseases [15, 18,
48]. Transforming growth factor-b has been described as a
modulator of the synthesis of extracellular matrix components [49,
50]. In the present study we analyzed the effect of TGF-b1 on the
production of chemokines and complement by renal cells in vitro.
Previously we described the production and regulation of chemo-
kine and complement components by PTEC [37–39, 41, 51]. The
pro-inflammatory cytokines IL-1a and TNF-a were shown to
Fig. 2. Kinetics of chemokine and complement production by proximal tubule epithelial cells (PTEC) in the presence or absence of transforming
growth factor-B1 (TGF-b1). The PTEC lines 1 and 2 were incubated for various time periods in the absence (solid line) or presence (dashed line) of
0.6 ng/ml TGF-b1. At each time point the supernatants were collected and assessed for the production of interleukin-8 (IL-8; A), macrophage
chemoattractant phagocyte-1 (MCP-1; B), and complements C3 (C) and C4 (D). Data are depicted for PTEC-1 (A) and (B) and for PTEC-2 (C) and
(D). Each point represents the mean 6 SD (N 5 3).
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up-regulate the production of IL-8 and MCP-1, whereas IFN-g
down-regulated IL-8 production and up-regulated MCP-1 pro-
duction by PTEC. These data demonstrate that there is a tight
balance between the production of IL-8, MCP-1 and the influx of
monocytes or polymorphonuclear cells (PMNs).
It is known that TGF-b has a dual effect, for instance, it inhibits
the proliferation of mesangial cells at high concentrations, it has
a mitogenic effect at lower concentrations [52], and inhibits
monocyte chemotaxis at picogram concentrations [7]. In the
present study we found that over a dose response range of 0.2 to
1.8 ng/ml TGF-b1 up-regulated IL-8, while in the same dose
response range a suppression of MCP-1 production was found,
suggesting that the concentration of TGF-b1 at a certain site may
influence the type of infiltrating inflammatory cells. At higher
concentrations it was shown that TGF-b was able to inhibit the
production of IL-8 by endothelial cells [53]. At higher concentra-
tions of TGF-b1, namely at 3.0 and 6.0 ng/ml, plateau levels of
effect on PTEC were seen for the various parameters studied.
There were no significant differences compared to the use of the
1.8 ng/ml concentration of TGF-b1. Kinetic experiments revealed
that there was a time-dependent effect of TGF-b1. Moreover, the
time point at which the response to TGF-b1 was maximal differed
Fig. 3. Effect of a monoclonal antibody (mAb)
anti-TGF-b on the transforming growth factor-
B1 (TGF-b1) mediated production of
interleukin-8 (IL-8; A) and macrophage
chemoattractant phagocyte-1 (MCP-1; B).
Proximal tubular epithelial cells-1 (PTEC-1)
were incubated in the absence or presence of
0.6 ng/ml TGF-b1 alone or together with anti-
TGF-b mAb 2G7 or control mAb. After 48
hours the supernatants were collected and
assessed for chemokine production. Each bar
represents the mean 6 SD (N 5 3).
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per protein, suggesting a differential regulation by TGF-b1.
Incubation of PTEC with TGF-b1 in the presence of a neutraliz-
ing antibody against TGF-b supported the notion that the effects
observed were specific for TGF-b1. Interesting was the observa-
tion that anti-TGF-b1 did not alter the spontaneous production of
IL-8 or MCP-1. Since significant effects of TGF-b1 on chemokine
production by PTEC were observed at doses higher than 0.6
ng/ml, we feel that the contribution of TGF-b1 produced in the
system does not substantialy influence the effect of exogenously
added TGF-b1. In accordance with that hypothesis, supernatants
of PTEC cultured under serum free conditions contained less
than 50 pg/ml of TGF-b1.
In previous studies we demonstrated that cytokines, such as
IL-1a, IL-2 and interferon-gamma (IFN-g), were able to up-
regulate the production of either C3 or C4 [40–42, 54]. Since
TGF-b has been shown to be present in the various forms of renal
disease [15, 17–19], one could speculate that the production of the
complement components can be regulated by TGF-b1 or by other
cytokines. In the present study TGF-b1 reduced the production of
C3 and C4 in a dose- and time-dependent fashion. No effects were
observed for the other complement components known to be
produced by PTEC such as C2 and factor H. Expression of
complement C3 and C4 has been found in various renal diseases
such as systemic lupus erythematosis (SLE), membranoprolifera-
tive glomerulonephritis, tubulointerstitial nephritis and renal al-
lograft rejection [33, 55–57]. A dual effect of TGF-b on comple-
ment C3 production was demonstrated for two different cell types.
Transforming growth factor-b was shown to induce C3 synthesis
in monocytes, whereas in astrocytes an inhibition of cytokine-
induced C3 expression was found [10, 58]. In this respect a
number of the effects of TGFb-1 on PTEC are in agreement with
the expectation upon down-regulation of MCP-1 and up-regula-
tion of IL-8. However, the effects on complement production are
different from that observed in monocytes. Additional studies are
required to analyze the reason for these differences.
The role of TGF-b on tubular cells is not only restricted to
chemokine and complement production. Transforming growth
factor-b has also been shown to play an role on the production of
extracellular matrix proteins by several tubular cells of non-
human origin [59, 60]. Furthermore, it has been shown that rabbit
proximal tubular epithelial cells possess a receptor for TGF-b
[61]. Since mRNA expression of TGF-b occurs in several types of
glomerulonephritis and renal allograft rejection, and because the
expression of chemokines and complement component mRNAs in
situ in tubular cells in several types of glomerular nephritis and
renal allograft rejection have been reported [26, 33, 55, 62–64], it
might be possible that TGF-b is involved in the local regulation of
chemokine and complement component production by tubular
cells. In the present study the major emphasis was placed on the
effect of TGF-b1 on PTEC. Studies employing TGF-b2 indicated
similar degrees of up-regulation of IL-8 as that seen with TGF-b1.
Optimal effects of TGF-b2 were found in a dose range of 0.3 to
2.6 ng/ml, both for IL-8 up-regulation and for MCP-1 down-
regulation. Unfortunately, we did not have access to TGF-b3.
The data obtained in this study, together with our previous
studies on cytokine regulated expression of chemokines and
complement production by PTEC [37, 38, 40, 41], suggest that a
relationship between the expression of chemokines and comple-
ment by tubular cells and the cytokines expressed during this
inflammation might exist together to regulate the influx of inflam-
matory cells and degree of local inflammation.
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APPENDIX
Abbreviations used in this study are: ADBP/CD26, anti-adenosine
deaminase binding protein antibody; CD32, IgG Fc receptor type II;
CD89, FcaR; DFCS, decomplimented fetal calf serum; IL-8, interleukin-8;
LAP, anti-leucine amino peptidase antibody; MCP-1, macrophage che-
moattractant phagocyte-1; MoAb, monoclonal antibody; PMN, polymor-
phonuclear; PTEC, proximal tubular epithelial cells; SLE, systemic lupus
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